248 related articles for article (PubMed ID: 29670214)
41. Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.
Isakov O; Wallis D; Evans DG; Ben-Shachar S
EBioMedicine; 2018 Oct; 36():508-516. PubMed ID: 30274822
[TBL] [Abstract][Full Text] [Related]
42. Decreased expression of neurofibromin contributes to epithelial-mesenchymal transition in neurofibromatosis type 1.
Arima Y; Hayashi H; Kamata K; Goto TM; Sasaki M; Kuramochi A; Saya H
Exp Dermatol; 2010 Aug; 19(8):e136-41. PubMed ID: 20002172
[TBL] [Abstract][Full Text] [Related]
43. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
[TBL] [Abstract][Full Text] [Related]
44. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
45. Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.
Führer S; Tollinger M; Dunzendorfer-Matt T
J Mol Biol; 2019 Sep; 431(19):3889-3899. PubMed ID: 31401120
[TBL] [Abstract][Full Text] [Related]
46. Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction.
Xu J; Ismat FA; Wang T; Lu MM; Antonucci N; Epstein JA
Circ Res; 2009 Jul; 105(3):304-11. PubMed ID: 19574548
[TBL] [Abstract][Full Text] [Related]
47. PKA phosphorylation and 14-3-3 interaction regulate the function of neurofibromatosis type I tumor suppressor, neurofibromin.
Feng L; Yunoue S; Tokuo H; Ozawa T; Zhang D; Patrakitkomjorn S; Ichimura T; Saya H; Araki N
FEBS Lett; 2004 Jan; 557(1-3):275-82. PubMed ID: 14741381
[TBL] [Abstract][Full Text] [Related]
48. The motor protein kinesin-1 links neurofibromin and merlin in a common cellular pathway of neurofibromatosis.
Hakimi MA; Speicher DW; Shiekhattar R
J Biol Chem; 2002 Oct; 277(40):36909-12. PubMed ID: 12191989
[TBL] [Abstract][Full Text] [Related]
49. The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis.
Luscan A; Shackleford G; Masliah-Planchon J; Laurendeau I; Ortonne N; Varin J; Lallemand F; Leroy K; Dumaine V; Hivelin M; Borderie D; De Raedt T; Valeyrie-Allanore L; Larousserie F; Terris B; Lantieri L; Vidaud M; Vidaud D; Wolkenstein P; Parfait B; Bièche I; Massaad C; Pasmant E
Clin Cancer Res; 2014 Jan; 20(2):358-71. PubMed ID: 24218515
[TBL] [Abstract][Full Text] [Related]
50. Neurofibromin Structure, Functions and Regulation.
Bergoug M; Doudeau M; Godin F; Mosrin C; Vallée B; Bénédetti H
Cells; 2020 Oct; 9(11):. PubMed ID: 33121128
[TBL] [Abstract][Full Text] [Related]
51. Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.
Stansfield BK; Bessler WK; Mali R; Mund JA; Downing BD; Kapur R; Ingram DA
Am J Pathol; 2014 Jan; 184(1):79-85. PubMed ID: 24211110
[TBL] [Abstract][Full Text] [Related]
52. Neurofibromatosis type 1 alternative splicing is a key regulator of Ras/ERK signaling and learning behaviors in mice.
Nguyen HT; Hinman MN; Guo X; Sharma A; Arakawa H; Luo G; Lou H
Hum Mol Genet; 2017 Oct; 26(19):3797-3807. PubMed ID: 28934393
[TBL] [Abstract][Full Text] [Related]
53. Alternative splicing of the neurofibromatosis type I pre-mRNA.
Barron VA; Lou H
Biosci Rep; 2012 Apr; 32(2):131-8. PubMed ID: 22115364
[TBL] [Abstract][Full Text] [Related]
54. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1.
Stowe IB; Mercado EL; Stowe TR; Bell EL; Oses-Prieto JA; Hernández H; Burlingame AL; McCormick F
Genes Dev; 2012 Jul; 26(13):1421-6. PubMed ID: 22751498
[TBL] [Abstract][Full Text] [Related]
55. NF1 and Neurofibromin: Emerging Players in the Genetic Landscape of Desmoplastic Melanoma.
Mahalingam M
Adv Anat Pathol; 2017 Jan; 24(1):1-14. PubMed ID: 27941538
[TBL] [Abstract][Full Text] [Related]
56. The pre-GAP-related domain of neurofibromin regulates cell migration through the LIM kinase/cofilin pathway.
Starinsky-Elbaz S; Faigenbloom L; Friedman E; Stein R; Kloog Y
Mol Cell Neurosci; 2009 Dec; 42(4):278-87. PubMed ID: 19666124
[TBL] [Abstract][Full Text] [Related]
57. Neurofibromin is a novel regulator of Ras-induced reactive oxygen species production in mice and humans.
Bessler WK; Hudson FZ; Zhang H; Harris V; Wang Y; Mund JA; Downing B; Ingram DA; Case J; Fulton DJ; Stansfield BK
Free Radic Biol Med; 2016 Aug; 97():212-222. PubMed ID: 27266634
[TBL] [Abstract][Full Text] [Related]
58. Neurofibromin and NF1 gene analysis in composite pheochromocytoma and tumors associated with von Recklinghausen's disease.
Kimura N; Watanabe T; Fukase M; Wakita A; Noshiro T; Kimura I
Mod Pathol; 2002 Mar; 15(3):183-8. PubMed ID: 11904334
[TBL] [Abstract][Full Text] [Related]
59. Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1).
Schindeler A; Little DG
Bone; 2008 Apr; 42(4):616-22. PubMed ID: 18248783
[TBL] [Abstract][Full Text] [Related]
60. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway.
Feldkamp MM; Angelov L; Guha A
Surg Neurol; 1999 Feb; 51(2):211-8. PubMed ID: 10029430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
